Entries by Georg Kääb

Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom

The company Captain T Cell, spin-out from Max-Delbrück center in Berlin, now has a total of €20 million in funding and grants to push forward its novel cell therapies for solid tumours. New backers include Springboard Health Angels, Pluton Asset Holding, Sintra Limited and the Technologiegründerfonds Sachsen, joining the existing investor base. The new tennant in Bayer´s Co.Lab in Berlin City does starts with positive vibes.

Solid tumours meet their match

Solid tumours pose major obstacles for cell therapies, but German-American biotech T-knife is tackling them head-on. CEO Tom Soloway and CTO Elisa Kieback share how their “supercharged” TCR-Ts are engineered to overcome these challenges.

Tubulis secures €308m in record-breaking Series C financing  

Munich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.

British Owlstone Medical wins ARPA-H award, but will it materialize?

Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?

Abivax soars 500% on TOP-Line data

In a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.